The use of selective estrogen receptor modulators on bone health in men

Selective estrogen receptor modulators (SERMs) represent a class of drugs that act as agonist or antagonist for estrogen receptor in a tissue-specific manner. The SERMs drugs are initially used for the prevention and treatment of osteoporosis in postmenopausal women. Bone health in prostate cancer p...

Full description

Saved in:
Bibliographic Details
Published in:The aging male 2019-04, Vol.22 (2), p.89-101
Main Authors: Wong, Sok Kuan, Mohamad, Nur-Vaizura, Jayusman, Putri Ayu, Shuid, Ahmad Nazrun, Ima-Nirwana, Soelaiman, Chin, Kok-Yong
Format: Article
Language:English
Subjects:
Bone density
Bones
Estrogens
lasofoxifene
Mens health
Older people
Osteoporosis
Prostate cancer
raloxifene
tamoxifen
toremifene
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Selective estrogen receptor modulators (SERMs) represent a class of drugs that act as agonist or antagonist for estrogen receptor in a tissue-specific manner. The SERMs drugs are initially used for the prevention and treatment of osteoporosis in postmenopausal women. Bone health in prostate cancer patients has become a significant concern, whereby patients undergo androgen deprivation therapy is often associated with deleterious effects on bone. Previous preclinical and epidemiological findings showed that estrogens play a dominant role in improving bone health as compared to testosterone in men. Therefore, this evidence-based review aims to assess the available evidence derived from animal and human studies on the effects of SERMs on the male skeletal system. The effects of SERMs on bone mineral density (BMD)/content (BMC), bone histomorphometry, bone turnover, bone strength and fracture risk have been summarized in this review.
ISSN:1368-5538
1473-0790
DOI:10.1080/13685538.2018.1448058